SCHEMBL1464484

SCHEMBL1464484

N#CN=C1c2cc(-c3cc(F)cc(Cl)c3)ccc2OC12CCc1ccccc1CC2

nearest known ligand 0.44

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 11/20 0.44
PGR P06401 4/20 0.32
CTSD P07339 2/20 0.32
CTSB P07858 2/20 0.31
MAP4K4 O95819 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1464483 1.00 BACE1 (0.44) BACE1PGRCTSDCTSBMAP4K4
SCHEMBL12746141 0.88 BACE1 (0.47) BACE1PGRCTSDCTSBMAP4K4
SCHEMBL1465053 0.81 BACE1 (0.48) BACE1PGRCTSDCTSBMAP4K4
SCHEMBL1464156 0.77 BACE1 (0.41) BACE1
SCHEMBL27853 0.68 PGR (0.39) BACE1PGRCTSDCTSBMAP4K4
SCHEMBL1465924 0.63 BACE1 (0.49) BACE1
SCHEMBL1465921 0.63 BACE1 (0.49) BACE1
SCHEMBL2374777 0.61 BACE1 (0.44) BACE1PGR
SCHEMBL2374775 0.61 BACE1 (0.44) BACE1PGR
SCHEMBL12746143 0.61 BACE1 (1.00) BACE1CTSD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10336717-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, LLC (US) 2019-07-02 US disclosed
US-20160272600-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, LLC 2016-09-22 US disclosed
EP-2406240-B1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS INC (US) 2015-12-23 EP disclosed
US-9212153-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2015-12-15 US disclosed
EP-2801570-A1 Inhibitors of beta-secretase Vitae Pharmaceuticals, Inc. (US) 2014-11-12 EP disclosed
US-20140200223-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. 2014-07-17 US disclosed
US-8633212-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-01-21 US disclosed
US-20110071126-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. 2011-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140200223-A1 INHIBITORS OF BETA-SECRETASE BACE1, BACE2, PSEN1 BACE1 1/4885PGR 4426/4885CTSD 52/4885
US-10336717-B2 Inhibitors of beta-secretase BACE1, BACE2, PSEN1 BACE1 1/4885PGR 4426/4885CTSD 52/4885
US-20160272600-A1 INHIBITORS OF BETA-SECRETASE BACE1, BACE2, PSEN1 BACE1 1/4885PGR 4426/4885CTSD 52/4885
US-20110071126-A1 INHIBITORS OF BETA-SECRETASE BACE1, BACE2, PSEN1 BACE1 1/4885PGR 4426/4885CTSD 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.